Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer's Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder

被引:330
|
作者
Kamat, Pradip K. [1 ]
Kyles, Philip [1 ]
Kalani, Anuradha [1 ]
Tyagi, Neetu [1 ,2 ]
机构
[1] Univ Louisville, Dept Physiol & Biophys, Sch Med, Louisville, KY 40202 USA
[2] Univ Louisville, Hlth Sci Ctr, Dept Physiol & Biophys, A-1201, Louisville, KY 40202 USA
基金
美国国家卫生研究院;
关键词
Homocysteine; Blood-brain barrier dysfunction; Cerebrovascular pathology; Alzheimer's disease; Dementia; INDUCED MEMORY IMPAIRMENT; PLASMA HOMOCYSTEINE; MATRIX METALLOPROTEINASES; COGNITIVE PERFORMANCE; RECEPTOR TRAFFICKING; RISK-FACTOR; RAT-BRAIN; MATRIX-METALLOPROTEINASE-9; EXPRESSION; DEMENTIA;
D O I
10.1007/s12035-015-9212-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Elevated plasma total homocysteine (Hcy) level is associated with an increased risk of Alzheimer's disease (AD). During transsulfuration pathways, Hcy is metabolized into hydrogen sulfide (H2S), which is a synaptic modulator, as well as a neuro-protective agent. However, the role of hydrogen sulfide, as well as N-methyl-d-aspartate receptor (NMDAR) activation, in hyperhomocysteinemia (HHcy) induced blood-brain barrier (BBB) disruption and synaptic dysfunction, leading to AD pathology is not clear. Therefore, we hypothesized that the inhibition of neuronal NMDA-R by H2S and MK801 mitigate the Hcy-induced BBB disruption and synapse dysfunction, in part by decreasing neuronal matrix degradation. Hcy intracerebral (IC) treatment significantly impaired cerebral blood flow (CBF), and cerebral circulation and memory function. Hcy treatment also decreases the expression of cystathionine-beta-synthase (CBS) and cystathionine-gamma-lyase (CSE) in the brain along with increased expression of NMDA-R (NR1) and synaptosomal Ca2+ indicating excitotoxicity. Additionally, we found that Hcy treatment increased protein and mRNA expression of intracellular adhesion molecule 1 (ICAM-1), matrix metalloproteinase (MMP)-2, and MMP-9 and also increased MMP-2 and MMP-9 activity in the brain. The increased expression of ICAM-1, glial fibrillary acidic protein (GFAP), and the decreased expression of vascular endothelial (VE)-cadherin and claudin-5 indicates BBB disruption and vascular inflammation. Moreover, we also found decreased expression of microtubule-associated protein 2 (MAP-2), postsynaptic density protein 95 (PSD-95), synapse-associated protein 97 (SAP-97), synaptosomal-associated protein 25 (SNAP-25), synaptophysin, and brain-derived neurotrophic factor (BDNF) showing synapse dysfunction in the hippocampus. Furthermore, NaHS and MK801 treatment ameliorates BBB disruption, CBF, and synapse functions in the mice brain. These results demonstrate a neuro-protective effect of H2S over Hcy-induced cerebrovascular pathology through the NMDA receptor. Our present study clearly signifies the therapeutic ramifications of H2S for cerebrovascular diseases such as Alzheimer's disease.
引用
收藏
页码:2451 / 2467
页数:17
相关论文
共 50 条
  • [31] Blood-Brain Barrier Breakdown in Alzheimer's Disease: Mechanisms and Targeted Strategies
    Alkhalifa, Amer E.
    Al-Ghraiybah, Nour F.
    Odum, Julia
    Shunnarah, John G.
    Austin, Nataleigh
    Kaddoumi, Amal
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (22)
  • [32] Blood-brain barrier P-glycoprotein function in Alzheimer's disease
    van Assema, Danielle M. E.
    Lubberink, Mark
    Bauer, Martin
    van der Flier, Wiesje M.
    Schuit, Robert C.
    Windhorst, Albert D.
    Comans, Emile F. I.
    Hoetjes, Nikie J.
    Tolboom, Nelleke
    Langer, Oliver
    Mueller, Markus
    Scheltens, Philip
    Lammertsma, Adriaan A.
    van Berckel, Bart N. M.
    BRAIN, 2012, 135 : 181 - 189
  • [33] Blood-brain barrier permeable β-blockers linked to lower risk of Alzheimer's disease in hypertension
    Beaman, Emily Eufaula
    Bonde, Anders Nissen
    Larsen, Sara Marie Ulv
    Ozenne, Brice
    Lohela, Terhi Johanna
    Nedergaard, Maiken
    Gislason, Gunnar Hilmar
    Knudsen, Gitte Moos
    Holst, Sebastian Camillo
    BRAIN, 2023, 146 (03) : 1141 - 1151
  • [34] Blood-Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease
    Shin, Yoojin
    Choi, Se Hoon
    Kim, Eunhee
    Bylykbash, Enjana
    Kim, Jeong Ah
    Chung, Seok
    Kim, Doo Yeon
    Kamm, Roger D.
    Tanzi, Rudolph E.
    ADVANCED SCIENCE, 2019, 6 (20)
  • [35] Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study
    Starr, John M.
    Farrall, Andrew J.
    Armitage, Paul
    McGurn, Brian
    Wardlaw, Joanna
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2009, 171 (03) : 232 - 241
  • [36] Blood-brain barrier link to human cognitive impairment and Alzheimer's disease
    Barisano, Giuseppe
    Montagne, Axel
    Kisler, Kassandra
    Schneider, Julie A.
    Wardlaw, Joanna M.
    Zlokovic, Berislav V.
    NATURE CARDIOVASCULAR RESEARCH, 2022, 1 (02): : 108 - 115
  • [37] Choline Supplementation Ameliorates Behavioral Deficits and Alzheimer's Disease-Like Pathology in Transgenic APP/PS1 Mice
    Wang, Yanyan
    Guan, Xingying
    Chen, Xuedan
    Cai, Yulong
    Ma, Yuanyuan
    Ma, Jiming
    Zhang, Qiming
    Dai, Limeng
    Fan, Xiaotang
    Bai, Yun
    MOLECULAR NUTRITION & FOOD RESEARCH, 2019, 63 (18)
  • [38] Drug delivery to the brain in Alzheimer's disease: Consideration of the blood-brain barrier
    Banks, William A.
    ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (07) : 629 - 639
  • [39] Microvascular injury and blood-brain barrier leakage in Alzheimer's disease
    Zipser, B. D.
    Johanson, C. E.
    Gonzalez, L.
    Berzin, T. M.
    Tavares, R.
    Hulette, C. M.
    Vitek, M. P.
    Hovanesian, V.
    Stopa, E. G.
    NEUROBIOLOGY OF AGING, 2007, 28 (07) : 977 - 986
  • [40] Effects of oxysterols on the blood-brain barrier: Implications for Alzheimer's disease
    Gosselet, Fabien
    Saint-Pol, Julien
    Fenart, Laurence
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 446 (03) : 687 - 691